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Objective: SCN8A encephalopathy (early infantile epileptic encephalopathy; EIEE13) is
caused by gain-of-function mutations resulting in hyperactivity of the voltage-gated
sodium channel Nav1.6. The channel is concentrated at the axon initial segment (AIS)
and is involved in establishing neuronal excitability. Clinical features of SCN8A
encephalopathy include seizure onset between 0 and 18 months of age, intellectual
disability, and developmental delay. Seizures are often refractory to treatment with
standard antiepileptic drugs, and sudden unexpected death in epilepsy (SUDEP) has
been reported in approximately 10% of patients. In a recent study, high doses of pheny-
toin were effective in four patients with SCN8A encephalopathy. In view of this observa-
tion, we have investigated the relationship between the functional effect of the SCN8A
mutation p.Ile1327Val and its response to phenytoin.
Methods: Themutation was introduced into the Scn8a cDNA by site-directedmutage-
nesis. Channel activity was characterized in transfected ND7/23 cells. The effects of
phenytoin (100 lM) onmutant andwild-type (WT) channels were compared.
Results: Channel activation parameters were shifted in a hyperpolarizing direction in
the mutant channel, whereas inactivation parameters were shifted in a depolarizing
direction, increasing Na channel window current. Macroscopic current decay was slo-
wed in I1327V channels, indicating an impairment in the transition from open state to
inactivated state. Channel deactivation was also delayed, allowing more channels to
remain in the open state. Phenytoin (100 lM) resulted in hyperpolarized activation and
inactivation curves as well as greater tonic block and use-dependent block of I1327V
mutant channels relative toWT.
Significance: SCN8A – I1327V is a gain-of-function mutation with altered features that
are predicted to increase neuronal excitability and seizure susceptibility. Phenytoin is
an effective inhibitor of the mutant channel andmay be of use in treating patients with
gain-of-functionmutations of SCN8A.
KEY WORDS: SCN8A, Anticonvulsant drugs, Sodium channels, Epileptic
encephalopathy, Phenytoin.
Sodium (Na) channels play a critical role in controlling
neuronal excitability because they are directly involved in
action potential generation and conduction, and also play a
role in the transition between single spiking and bursting in
some neurons.1 Proexcitatory alterations in Na channel
function have been reported in patients with epilepsy,2,3 and
in animal models of epilepsy.4,5 The Na channel isoform
Nav1.6 is encoded by the SCN8A gene and is highly local-
ized along the axonal initial segment (AIS),6 the site of
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action potential generation, and at the nodes of Ranvier.7 In
some acquired epilepsy, Nav1.6 expression is increased,
4,5
and reducing Nav1.6 has been shown to impair the initiation
and development of kindled seizures.4
De novo missense mutations of SCN8A are associated
with early infantile epileptic encephalopathy (EIEE).26
Since the discovery of the first mutation,8 >100 additional
mutations have been identified and collectively defined as
EIEE13.3 Most patients with EIEE13 have seizure onset
between birth and 12 months of age, with a median age of
onset of 4 months. After the onset of seizures, there is sig-
nificant developmental regression that results in mild to sev-
ere intellectual disability. Sudden unexpected death in
epilepsy (SUDEP) has been reported in approximately 10%
of patients.
Electrophysiology studies on a limited number of muta-
tions demonstrate that many have a gain-of-function charac-
teristic.8,10,15 Of interest, the mechanism by which this
proexcitatory endpoint is achieved differs among the muta-
tions. In some, there is an increase in persistent Na current
and proexcitatory shifts in channel inactivation parameters,
whereas in others there is a leftward shift in the voltage
dependence of activation. A knock-in mouse model carry-
ing the SCN8A mutation p.Asn1768Asp possesses many of
the pathologic phenotypes seen in human patients, including
seizures and sudden death.11
Because the seizures in many EIEE13 patients are associ-
ated with a gain-of-function in Na channel activity, a
rational approach to therapy would be to use anticonvul-
sants with Na channel blocking characteristics. However,
the seizures in EIEE13 patients are difficult to control even
with Na channel blockers, and many patients remain refrac-
tory. A recent study of four children with EIEE13 demon-
strated good seizure control with high doses of phenytoin.12
One of these patient mutations included in the study has
been examined functionally and shown to result in a
hyperpolarizing shift in voltage dependence of activation.9
In the current study, we determined the biophysical proper-
ties of another SCN8A mutation, p.Ile1327Val, located
within the highly conserved region of transmembrane seg-
ment 5 adjacent to the cytosolic interface of the S4–S5 lin-
ker of domain III.13,19 Our data show that I1327V is a gain-
of-function mutation that is predicted to lead to increased
neuronal activity and the generation of seizures. We demon-
strate that phenytoin (100 lM) results in greater tonic block
and use-dependent block of I1327V channels compared
with WT channels. The preferential effect of phenytoin on
the mutant channel may increase the effectiveness of pheny-
toin in treating refractory seizures associated with EIEE13.
Methods
Site-directed mutagenesis of the Nav1.6 cDNA
The amino acid substitution I1327V was introduced into
the tetrodotoxin (TTX)–resistant derivative of the full-length
rNav1.6 cDNA clone (NM_014191.3, NP_055006.1),
14 as
described previously.8,9,15 Site-directed mutagenesis was
carried out with the QuikChange II XL kit (Agilent Tech-
nologies). The entire 6-kb open reading frame was
sequenced to confirm the absence of other mutations.
Cell culture
Dorsal root ganglion (DRG)-neuron derived ND7/23
cells (Sigma Aldrich) were grown in a humidified atmo-
sphere of 5% CO2 and 95% air at 37⁰C in Dulbecco’s Modi-
fied Eagle Medium (DMEM 19) supplemented with 10%
Fetal Bovine Serum (FBS), Non-Essential Amino Acid
(NEAA), and sodium pyruvate. Cells were plated onto petri
dishes 48 h prior to transfection and transfected for 5 h in
nonsupplemented DMEM using lipofectamine 3000 accord-
ing to manufacturer instructions (Life Technologies) with
5 lg of Nav1.6 alpha subunit cDNA and 0.5 lg of the fluo-
rescent m-Venus bioreporter. Electrophysiologic recordings
of fluorescent cells were made 48 h after transfection.
Electrophysiology
Recordings were carried out in the presence of 500 nM
TTX to block endogenous sodium currents in the neuron-
derived ND7/23 cells. Currents were recorded using the
whole-cell configuration of the patch-clamp recording tech-
nique as described previously.15 Currents were amplified
and low-pass filtered (2 kHz) and sampled at 33 kHz. The
intracellular recording solution contained (in mM): 140 CsF,
2 MgCl2, 1 EGTA, 10 HEPES, 4 Na2ATP, 0.3 NaGTP (pH
adjusted to 7.2 with CsOH, osmolarity adjusted to
300 mOsm with sucrose). Cultured ND7/23 cells were
bathed in solution containing (in mM): 130 NaCl, 3 KCl, 1
CaCl2, 5 MgCl2, 0.1 CdCl2, 10 HEPES, 30 TEA (pH
adjusted to 7.4 with NaOH, osmolarity adjusted to
310 mOsm with sucrose). Experiments were performed at
room temperature (20–22°C). After establishing the whole
Key Points
• The SCN8A mutation I1327V was previously identi-
fied in two patients with early infantile epileptic
encephalopathy (EIEE13)
• Electrophysiologic analysis of I1327V demonstrated
altered activation and inactivation parameters that are
pro-excitatory
• Deactivation and transition from open state to inacti-
vated state were impaired
• The effect of the anticonvulsant drug phenytoin on
tonic inhibition and use-dependent block was greater
on mutant than on wild-type channels
• Phenytoin may be effective in suppressing seizures in
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cell configuration, a minimum series resistance compensa-
tion of 75% was applied. Capacitive and leak currents were
subtracted using the P/4 protocol for all experiments, except
steady-state inactivation protocols. The current–voltage
relationship was determined using a 100 msec voltage pulse
from 80 to +70 mV in steps of 5 mV from a holding
potential of 120 mV at 2 s intervals. Conductance as a
function of voltage was derived from the current–voltage
relationship and fitted by a Boltzmann function as
described.5 Decays of macroscopic currents were fitted to a
single exponential function, and time constants were deter-
mined. For steady-state inactivation, neurons were held at
120 mV and test potentials from 115 to 10 mV for
500 msec at 5 mV increments were applied. The second
pulse to 10 mV for 40 msec was used to assess channel
availability. Correction for passive and leak currents was
achieved by subtracting the last sweep with the greatest
depolarizing potential (10 mV), since this sweep displays
no sodium channel current. Currents during the second
pulse were normalized for each cell with the largest current
as 1.0 and fit to the Boltzmann function. Deactivation was
estimated from current decay, using a 0.5 msec short depo-
larizing pulse to 10 mV followed by a 50 msec repolariz-
ing pulse to potentials ranging from 40 to 120 mV at
5 mV increments. Deactivation kinetics were determined
by fitting decaying currents with a single exponential func-
tion. For recovery from inactivation, cells were held at
120 mV and depolarized to a test potential of 0 mV for
1 s to inactivate Na channels. Recovery was determined at
times between 1 msec and 60 s at a test potential of
90 mV. A 40 msec pulse to 10 mV was subsequently
applied to assess the extent of channel recovery. For each
cell, current amplitudes during the test pulse were normal-
ized so that the largest current during the conditioning
potential was 1.0. Data were then fit to a double exponential
function as described previously.5
For experiments involving the testing of phenytoin, elec-
trophysiologic protocols under control, drug-free conditions
were obtained before bath application of phenytoin
(100 lM; 10 min).
Data analysis
Data represent means  standard error of the mean
(SEM). Statistical significance was determined using a Stu-
dent’s t-test or a standard one way analysis of variance
(ANOVA) followed by Tukey’s or Dunn’s post hoc test for
parametric data or the rank sum test for nonparametric data
(GraphPad Prism 6).
Results
Electrophysiologic characterization of I1327V
Isoleucine residue 1327 is located in the highly conserved
region of transmembrane segment 5 of domain III (D3S5)
adjacent to the cytosolic S4–S5 linker of Nav1.6 (Fig. 1A).
Representative currents from ND7/23 cells transfected with
WT and I1327V Nav1.6 are shown in Figure 1B. Peak cur-
rent density for I1327V was not elevated compared to WT
(Fig. 1C). Analysis of steady-state kinetics demonstrates a
small but significant hyperpolarizing shift in the half maxi-
mal voltage dependence of activation for I1327V (V1/2) of
2.5 mV (p < 0.05: Fig. 1D,E). Slope factor (k) was also
significantly decreased (p < 0.005: Fig. 1F, Table 1). To
determine the kinetics of open state inactivation, macro-
scopic current decay was fit to single exponential functions
and the fast time constant (Ƭ) was plotted as a function of
voltage. Transition from open state to the inactivated state
was significantly delayed in I1327V channels at depolariz-
ing voltages ranging between +15 and +35 mV (Fig. 1G),
consistent with the prediction of disrupted inactivation. The
slowing of fast inactivation is evident when the peaks of the
current traces at +35 mV are aligned so that inactivation
kinetics can be compared directly (Fig. 1H). When exam-
ined at a time point of 100 msec after the voltage stimulus,
decay of macroscopic current was complete for both
I1327V and WT, indicating the absence of increased persis-
tent current in the mutant channel (data not shown).
We next determined the effects of I1327V on the kinetics
of channel deactivation. Compared to WT channels,
I1327V significantly increased the time constant (Ƭ) of
deactivation over the range of voltages between 55 and
40 mV (Fig. 2A), indicating a slower transition from the
open state back to the closed state. Disruption in normal
inactivation processes have been described for several
SCN8Amutations.15 In I1327V channels, a significant depo-
larizing shift in the V1/2 of steady-state inactivation was
recorded (5.7 mV; p < 0.005: Fig. 2B,C) with no change in
slope values (Fig. 2D). Window currents can be determined
by taking the area under the overlapping normalized activa-
tion and inactivation curves (Fig. 2E).16 We determined the
window current for I1327V and WT channels and found an
increase in the window current for the mutant channel
(Fig. 2F). Finally, we examined recovery from inactivation
using a recovery voltage of 90 mV and found no signifi-
cant difference between WT and I1327V transfected cells
(Fig. 2G; Table 1).
Inhibition of I1327V by phenytoin
The antiepileptic drug (AED) phenytoin (Dilantin) is
clinically used to treat epileptic seizures. The mechanism is
thought to involve the inhibition of Na channels.17 Pheny-
toin binds preferentially to the inactivated form of Nav1.6,
and the drug can block high frequency firing of action
potentials, thereby trapping channels in the inactivated
state.17 Because I1327V displayed disrupted inactivation
parameters, we sought to determine if phenytoin would inhi-
bit currents evoked from a holding potential of 60 mV, a
potential when many of the channels can cycle between the
closed, open, and inactivated states. At a concentration of
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Table 1. Biophysical properties of I1327V andWT channels
Activation Inactivation Recovery
V1/2 k n V1/2 k n s1 s2 %Fast n
WT 18.3  0.9 6.6  0.2 10 69.4  1.8 7.3  0.2 19 390  85.8 6,614  799 47.6  0.1 19
I1327V 20.8  0.7* 7.5  0.2** 20 63.7  0.6** 7.3  0.2 33 577  50.8 6,020  380 45.2  0.1 33
n, number of cells; V1/2, voltage of half-maximal activation or inactivation; k, slope factor.
Values represent means  SEM.
Significance was determined by unpaired Student’s t-test *p < 0.05, **p < 0.005.
Figure 1.
I1327V modulates steady-state activation. (A) Four-domain structure of the voltage-gated Na channel a subunit shows that I1327V is
located at the cytosolic interface of the S4–S5 linker and transmembrane segment 5 of domain III. (B) Representative traces of families of
Na currents recorded from ND7/23 cells transfected with the indicated Nav1.6 cDNAs. (C) Averaged current-voltage (I–V) relationship
for cells expressing WT and I1327V. Peak currents were normalized to cell capacitance. (D) Voltage dependence of channel activation.
Smooth lines correspond to the least-squares fit when average data were fit to a single Boltzmann equation. (E) Scatter plot of voltage at
half-maximal activation (V1/2) for cells expressing WT and I1327V. (F) Scatter plot of the slope factor of activation (k). (G) Average fast
time constants obtained from single exponential fits to macroscopic current decays as a function of voltage. (H) Representative traces of
normalized currents evoked by a +35 mV stimulus from a holding potential of 120 mV illustrate delays in macroscopic current decay
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for I1327V (53  2.0%; n = 10) than WT currents
(43  2.0%; n = 8: p < 0.05; Fig. 3A,B). In addition to
voltage-dependent block, AEDs also exhibit use-dependent
block as an important mechanism of action, permitting
enhanced block of high-frequency neuronal firing associ-
ated with epileptic seizures.18 In a manner similar to that of
tonic block, phenytoin (100 lM) produced a greater use-
dependent block of I1327V channels compared to WT
(Fig. 3C). In the absence of phenytoin, there was very little
block of control (6.0  1.0%; n = 23) and I1327V
(7.0  1.0%; n = 29) channel currents during the use-
dependent protocol. In the presence of phenytoin, WT chan-
nels were blocked by 11  2.0% (n = 12) at pulse 60. In
contrast, phenytoin caused greater use-dependent block of
I1327V channels, blocking the current by 21  4.0%
(n = 9; p < 0.05).
Phenytoin (100 lM) also caused a hyperpolarizing shift
in the voltage dependence of activation for bothWT channel
(V1/2 by 7.6 mV; p < 0.05; Fig. 3D,E) and I1327V chan-
nels (V1/2 by 16.9 mV; p < 0.05: Fig. 3F,G). Phenytoin
had no effect on the slope (k) in WT or I1327V channels
(Table 2). Inactivation parameters were shifted
significantly in a hyperpolarized direction by phenytoin
(100 lM) for both WT (V1/2 by 15.4 mV; p < 0.05;
Fig. 4A–C) and I1327V (V1/2 by 13.0 mV; p < 0.005:
Fig. 4D–F). Slope factors (k) remained unchanged for both
WT and I1327V (Table 2). Phenytoin did not significantly
alter either the fast or slow time constants of recovery from
inactivation at 90 mV in either I1327V- or WT-trans-
fected cells (Table 2). Phenytoin did, however, significantly
decrease the amplitude of the Na current recorded after a
recovery interval of 60 s in WT (47.3  3.4% Fig. 4G) and
I1327V (33.6  11.3% Fig. 4H).
Discussion
The de novo mutation I1327V was identified in two unre-
lated patients with early onset encephalopathy.13,19 Residue
Ile1327 is located within the highly conserved region of
transmembrane segment D3S5 adjacent to the cytosolic
interface with the S4–S5 linker. Mutation studies indicate
that residues located along the S4–S5 linker of domain III
are critical to fast inactivation, since they provide an interac-
tion site for the fast inactivation gate.20 Because isoleucine
Figure 2.
I1327V disrupts channel inactivation properties. (A) Average fast time constant obtained from single exponential fits to deactivation of
WT and I1327V channels. (B) Voltage dependence of steady-state inactivation. Smooth lines correspond to the least-squares fit when
average data were fit to a single Boltzmann equation. (C) Scatter plot of voltage at half-maximal inactivation (V1/2) for cells expressingWT
and I1327V. (D) Scatter plot of the slope factor (k) of inactivation. (E) The window current is obtained by overlapping the normalized acti-
vation and inactivation curves from WT and I1327V cells. (F) Enhanced view of overlapping activation and inactivation curves shows an
increase in I1327V window current (red shaded area) compared toWT (gray shaded area). (G) Recovery from inactivation at a post train
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and valine are relatively similar in structure and both are
nonpolar, hydrophobic amino acids, the mechanisms behind
disrupted inactivation are not obvious. We hypothesize that
substituting the bulky isoleucine side chain with methyl and
ethyl groups, for the smaller valine side chain, composed
only of methyl groups, may disrupt the hydrogen bonds that
form between the inactivation gate and the S4–S5 linker of
domain III, disrupting the normal inactivation process.
Consistent with the gain-of-function mechanism, I1327V
resulted in a hyperpolarizing shift in activation parameters,
Figure 3.
Phenytoin (PHT) inhibits Na channel currents evoked fromWT and I1327V and modulates steady-state activation parameters. (A) Scat-
ter plot showing normalized macroscopic current amplitude remaining following tonic block by phenytoin (100 lM). Currents were eli-
cited by a depolarizing step to 0 mV for 12 msec from a holding potential of 60 mV. (B) Representative traces show greater tonic
inhibition of I1327V currents overWT currents by phenytoin (100 lM) (C) Use-dependent block by phenytoin (100 lM). Cells were held
at 120 mV and a voltage step to +20 mV was applied for 20 msec at a frequency of 10 Hz. (D) Shift in the voltage dependence of WT
channel activation following treatment with phenytoin (100 lM). Smooth lines correspond to the least squares fit when average data were
fit to a single Boltzmann equation. (E) Scatter plot of voltage at half-maximal activation (V1/2). (F) Shift in the voltage dependence of
I1327V channel activation following treatment with phenytoin (100 lM). Smooth lines correspond to the least squares fit when average
data were fit to a single Boltzmann equation. (G) Scatter plot of voltage at half-maximal activation (V1/2). Data are means  SEM. Statisti-
cal significance: *p < 0.05. Black filled circles, WT; blue open circles, WT + phenytoin, red filled triangles, I1327V; orange open triangles,
I1327V + phenytoin.
Epilepsia ILAE
Table 2. Phenytoin (100 lM)modulates the biophysical properties of I1327V andWT channels
Activation Inactivation Recovery
V1/2 k n V1/2 k n s1 s2 %Fast n
WT 24.9  1.8 6.3  0.2 9 66.2  4.1 7.2  0.3 6 181  95 4,405  1,196 56.4  0.1 7
WT + PHT 32.5  2.2* 5.8  0.5 9 81.6  5.1* 7.9  0.4 6 145  57 4,942  1,757 51.6  0.1 7
I1327V 23.5  2.6 7.3  0.2 6 65.3  2.0 7.4  0.4 9 423  205 8,668  122 44.4  0.1 5
I1327V + PHT 40.4  4.6* 6.2  0.5 6 78.3  2.7** 8.6  0.4 9 1,044  647 11,858  2,902 45.4  0.1 5
n, number of cells; V1/2, voltage of half-maximal activation or inactivation; k, slope factor.
Values represent means  SEM.
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Figure 4.
Phenytoin (PHT) modulates steady state inactivation properties in cells expressing WT and I1327V channels. (A) Shift in the voltage
dependence of WT channel inactivation following treatment with phenytoin (100 lM). Smooth lines correspond to the least-squares fit
when average data were fit to a single Boltzmann equation. (B) Scatter plot of voltage at half-maximal inactivation (V1/2). (C) Representa-
tive WT traces elicited following a pre-pulse to 75 mV demonstrating the shift in inactivation following application of phenytoin
(100 lM). Traces were normalized to the pre-phenytoin peak current. (D) Shift in the voltage dependence of I1327V channel inactivation
following treatment with phenytoin (100 lM). Smooth lines correspond to the least-squares fit when average data were fit to a single
Boltzmann equation. (E) Scatter plot of voltage at half-maximal inactivation (V1/2). (F) Representative I1327V traces following a pre-pulse
to75 mV demonstrating the shift in inactivation following the application of phenytoin (100 lM). Recovery from inactivation before and
after the application of phenytoin (100 lM) in WT (G) and I1327V (H) cells. Data are means  SEM. Statistical significance *p < 0.05;
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enabling mutant channels to open at voltages more negative
than WT channels. This shift, coupled with a depolarizing
shift in the voltage dependence of inactivation, would
extend the voltage range where channels would be available
for activation and have a finite probability of opening. This
range of voltages is commonly referred to as the window
current, and an enhancement in this current would reduce
action potential thresholds, thereby facilitating action
potential firing and potentially initiating seizure generation
and spread. Increases in window currents have been associ-
ated with increased persistent sodium current activity and
epileptogenesis in animal models.21,22 A delay in the decay
of the macroscopic current at depolarized voltages further
supports the view that a valine for isoleucine substitution at
position 1327 results in a major disruption of the normal
inactivation process in the mutant channel, specifically
delaying entry into the inactivated state. A slowing in chan-
nel deactivation would increase the availability of Na chan-
nels by delaying the transition of open channels back into
the closed state during short depolarizations, further
increasing the probability that channels remain in the open
state configuration for longer periods.
There is considerable heterogeneity among the 10
SCN8A mutations that have now been characterized
through electrophysiology studies. One common patho-
genic mechanism is a disruption in the inactivation process.
In some cases, including the current mutation I1327V, this
is due to a depolarizing shift in the inactivation curve that
delays channel inactivation,10 whereas other mutations
have normal voltage dependence of inactivation with an
increase in persistent Na channel current after prolonged
depolarization.8 Many of these mutations are located at
sites involved in channel inactivation, including domain
III, domain IV, and the C-terminus.3 In contrast, two muta-
tions located within transmembrane segments of domain II
have normal inactivation parameters, but establish a gain-
of-function phenotype via hyperpolarizing activation
curves, thereby increasing channel availability at more
negative membrane potentials and consequently increasing
window currents.9,10
AEDs that inhibit Na channels as a mechanism of action
have been used in treating seizures in patients with EIEE13.
However, it is unclear which AEDs should be considered
first for these patients. Furthermore, mechanistic studies
demonstrating the response of mutant channel currents to
AEDs are lacking. In a recent study of four patients with sei-
zures that were refractory to many AEDs, good seizure con-
trol was obtained with high-dose phenytoin.12 Withdrawal
of phenytoin resulted in seizure reoccurrence in all four
patients. This work suggests that phenytoin may be more
effective for SCN8A encephalopathy than other clinically
available AEDs. The mode of action of phenytoin includes
inhibition of Na channels, but it also effects calcium chan-
nels.17,23 Phenytoin has little effect on Na channels in their
resting or closed state, but at more depolarized potentials,
such as those observed during high frequency firing, the
block by phenytoin is pronounced.17,24 This greater affinity
for the inactivated state of the channel over the closed state
of the channel is an important characteristic of many
AEDs.25 When tested on the mutation I1327V, tonic block
and use-dependent block by phenytoin was more pro-
nounced for the mutant channel than for the WT channels.
A likely explanation is that phenytoin binds slowly to open
and inactivated channels.17 The mutant channel displayed
impaired deactivation kinetics and slowed transition from
the open state to the inactivated state at depolarized volt-
ages, allowing channels to remain longer in nonclosed con-
formation. Increased proportion of channels in open and
inactivated states would increase the time available for
phenytoin to bind tightly and trap the mutant channels in a
nonconducting conformation, thereby preventing them from
contributing to action potential initiation. This feature is
referred to as the modulated receptor hypothesis.27 Pheny-
toin also reversed the depolarizing shifts in inactivation
recorded with I1327V and caused further hyperpolarizing
shifts in activation curves. In view of these findings, patients
with the I1327V mutation may achieve good seizure control
with phenytoin in a manner similar to the patients reported
in the study by Boerma et al.12
The mutation described herein has been observed in two
patients to date. The first patient was a male child who expe-
rienced seizures immediately after birth and continued to
experience refractory epilepsy until his death at the age of
1 year and 5 months.13 It is unclear whether this patient
was treated with phenytoin. The second patient was a male
child who appeared to experience seizures in utero, per-
ceived as “drumming” sensations during the later stages of
pregnancy.19 Although several AEDs were unsuccessful at
providing seizure control in this patient, a high dose of
phenytoin (18–20 mg/L) did provide temporary seizure
control. Both patients had severe, early onset movement dis-
orders. Our study demonstrates that these patients had a
gain-of-function mutation of SCN8A, which likely
accounted for their epileptic encephalopathy. The effective-
ness of phenytoin at inhibiting the mutant channel currents
provides additional evidence that phenytoin may be a useful
treatment for SCN8A encephalopathy.
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